Group 1 - Xeris Biopharma reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of 33.33% [1] - The company posted revenues of $54.27 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 5.09%, and showing an increase from $48.32 million year-over-year [2] - Xeris Biopharma shares have increased approximately 43% since the beginning of the year, outperforming the S&P 500's gain of 25.2% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $52.86 million, and for the current fiscal year, it is -$0.40 on revenues of $193.2 million [7] - The Medical - Drugs industry, to which Xeris Biopharma belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8]

Group 1 - The article introduces a new contributing analyst specializing in private equity and venture capital, focusing on sectors such as deeptech, quantum technologies, biotechnology, pharmaceuticals, and energy transition [1] - The analyst emphasizes evaluating addressable markets and revenue growth potential through validated data points and organizational setups, particularly in cutting-edge sectors [1] - The approach taken by the analyst avoids deep dives into complex approval odds, instead focusing on value creation that supports company success [1] Group 2 - The analyst has disclosed a beneficial long position in the shares of XERS, initiated in early September [2] - The article clarifies that the views expressed are personal opinions and not influenced by any business relationships with mentioned companies [2] - It is noted that past performance does not guarantee future results, and no specific investment recommendations are provided [2]

Core Insights - The article discusses the investment strategy of Compounding Healthcare, which utilizes data analytics, technical analysis, and clinical data to identify potential multi-bagger investments in the healthcare sector [1]. Group 1 - Compounding Healthcare has been actively managing a diverse healthcare portfolio, focusing on innovative companies that develop breakthrough therapies and pharmaceuticals [1]. - The leader of Compounding Healthcare has a background in the medical field and emphasizes the importance of catalysts for potential acquisitions in the biotech sector [1]. - The article indicates that it has been approximately seven months since the last analysis on Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), during which a conservative investment stance was adopted while awaiting a strong reversal setup [1].

Core Viewpoint - Xeris Biopharma reported a quarterly loss of $0.10 per share, which was better than the Zacks Consensus Estimate of a loss of $0.11, indicating a positive earnings surprise of 9.09% [1] Financial Performance - The company posted revenues of $48.07 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 2.70% and showing an increase from $38.01 million in the same quarter last year [2] - Over the last four quarters, Xeris Biopharma has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Xeris Biopharma shares have declined approximately 9.4% since the beginning of the year, contrasting with the S&P 500's gain of 9% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting it is expected to outperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $49.45 million, and for the current fiscal year, it is -$0.39 on revenues of $189.5 million [7] - The estimate revisions trend for Xeris Biopharma is favorable ahead of the earnings release, which may influence future stock movements [6] Industry Context - The Medical - Drugs industry, to which Xeris Biopharma belongs, is currently ranked in the top 42% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, VYNE Therapeutics Inc., is expected to report a quarterly loss of $0.19 per share, reflecting a year-over-year change of +93.8% [9]

From a technical perspective, Xeris Biopharma Holdings, Inc. (XERS) is looking like an interesting pick, as it just reached a key level of support. XERS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world. There are three stages to a golden cross. First, there must be a downtrend in a stock's price that eventually bottoms out. Then, the stock's shorter moving average crosses over its longer moving average, triggering a posit ...

Group 1 - The company specializes in medium and small-cap markets while also providing updates on blue-chip companies, commodities, and broader investment stories to engage private investors [1] - The company is recognized as a forward-looking and enthusiastic adopter of technology [2] - Automation and software tools, including generative AI, are utilized by the company, but all content is edited and authored by humans to ensure quality and adherence to best practices [3] Group 2 - The publisher's news team operates from key financial hubs worldwide, including London, New York, Toronto, Vancouver, Sydney, and Perth [4] - Angela Harmantas, an editor with over 15 years of experience in equity markets, particularly in junior resource stocks, leads the content production [5] - The team provides news and insights across various sectors, including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [6]

Table of Contents UNITED STATES Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION (Exact name of the registrant as specified in its charte ...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Allison Wey - SVP, IR & Corporate Communications Paul Edick - Chairman & CEO Steven Pieper - CFO Conference Call Participants Oren Livnat - H.C. Wainwright & Co. Roanna Ruiz - Leerink Partners Rohan Mathur - Oppenheimer Kelly Close - Analyst Operator Hello, everyone, and welcome to the Xeris Biopharma First Quarter 2024 Financial Results Conference Call and Webcast. My name is Seth, and ...

[Q1 2024 Performance Highlights](index=1&type=section&id=First%20Quarter%202024%20Highlights) Xeris Biopharma reported a strong first quarter with total revenue of $40.6 million, a 22% increase year-over-year, tightening its full-year 2024 revenue guidance to $175-$200 million, and ending the quarter with a solid cash position of $87.4 million while securing significant new technology partnerships | Metric | Q1 2024 | Q1 2023 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | **Total Revenue** | $40.6M | $33.2M | +$7.4M | +22.4% | - Full-year 2024 total revenue guidance has been tightened to a range of **$175 million to $200 million**[1](index=1&type=chunk)[4](index=4&type=chunk) - Ended Q1 2024 with **$87.4 million** in cash, cash equivalents, and short-term investments, with the borrowing rate on Hayfin debt lowered by **2.05%**[1](index=1&type=chunk)[10](index=10&type=chunk) - Entered into a worldwide license agreement with Amgen for a XeriJect® formulation of teprotumumab and an exclusive worldwide agreement with Beta Bionics for a new XeriSol™ formulation of glucagon[1](index=1&type=chunk)[17](index=17&type=chunk) [Commercial Product Performance](index=1&type=section&id=Commercial%20Products) Total product revenue grew 25% to $40.3 million, primarily driven by a remarkable 137% surge in Recorlev sales, while Gvoke revenue increased by 10% to $16.6 million despite an estimated $3 million negative impact from the Change Healthcare cyberattack, and Keveyis sales remained resilient, growing 3% to $13.1 million | Product | Q1 2024 Net Revenue (in thousands) | Q1 2023 Net Revenue (in thousands) | % Change | | :--- | :--- | :--- | :--- | | Gvoke® | $16,579 | $15,033 | 10.3% | | Keveyis® | $13,085 | $12,755 | 2.6% | | Recorlev® | $10,599 | $4,477 | 136.7% | | **Total Product Revenue** | **$40,263** | **$32,265** | **24.8%** | - Gvoke's market share of the retail TRx glucagon market grew to over **36%** through late April 2024[6](index=6&type=chunk) - Recorlev's average number of patients increased by **139%** compared to Q1 2023 and **18%** compared to Q4 2023[6](index=6&type=chunk) - Gvoke revenue was negatively impacted by an estimated **$3 million** due to the Change Healthcare cyberattack[4](index=4&type=chunk) [Pipeline and Technology Partnerships](index=2&type=section&id=Pipeline%20and%20Technology%20Partnerships) The company advanced its pipeline by successfully completing the Phase 2 clinical study for XeriSol™ levothyroxine (XP-8121), with data expected mid-2024, and expanded its technology partnerships by signing an exclusive worldwide license with Amgen for its XeriJect® technology and a collaboration with Beta Bionics for its XeriSol™ technology - Successfully completed the Phase 2 clinical study for XeriSol™ levothyroxine (XP-8121); data is expected to be available in mid-2024[7](index=7&type=chunk) - Entered an exclusive worldwide license agreement with Amgen for a XeriJect® formulation of teprotumumab, making Xeris eligible for up to **$75 million** in milestones plus escalating single-digit royalties[17](index=17&type=chunk) - Signed an exclusive worldwide collaboration and license agreement with Beta Bionics to develop a new XeriSol™ liquid stable glucagon formulation for use in bi-hormonal pumps[17](index=17&type=chunk) [Financial Results Analysis](index=2&type=section&id=Financial%20Results%20Analysis) For Q1 2024, Xeris reported a net loss of $19.0 million, or $0.14 per share, driven by higher operating expenses, including a $3.0 million rise in R&D for pipeline investments and a $4.8 million increase in SG&A from higher personnel and rent costs, while maintaining a strong cash position of $87.4 million - Research and development (R&D) expenses increased by **$3.0 million** YoY, driven by investments in the XP-8121 pipeline program and technology partnerships[9](index=9&type=chunk) - Selling, general and administrative (SG&A) expenses rose by **$4.8 million** YoY, mainly due to higher personnel costs and rent for the new headquarters[10](index=10&type=chunk) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Net Loss | $19.0 million | $16.8 million | | Net Loss Per Share | $0.14 | $0.12 | - Cash, cash equivalents, and short-term investments totaled **$87.4 million** at March 31, 2024, an increase from **$72.5 million** at December 31, 2023[10](index=10&type=chunk) [Condensed Consolidated Financial Statements](index=4&type=section&id=Condensed%20Consolidated%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for Xeris Biopharma Holdings, Inc. as of March 31, 2024, including the Statement of Operations for the first quarter and the Balance Sheet at the end of the period [Condensed Consolidated Statements of Operations](index=4&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) For the three months ended March 31, 2024, total revenues increased to $40.6 million from $33.2 million in the prior-year period, offset by a rise in total costs and expenses to $54.9 million from $46.5 million, resulting in a net loss of $19.0 million, compared to a net loss of $16.8 million in Q1 2023 | (in thousands) | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | **Total revenue** | **$40,638** | **$33,196** | | Total costs and expenses | $54,883 | $46,473 | | Loss from operations | ($14,245) | ($13,277) | | **Net loss** | **($18,980)** | **($16,834)** | | Net loss per common share | ($0.14) | ($0.12) | [Condensed Consolidated Balance Sheets](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of March 31, 2024, total assets were $336.6 million, an increase from $322.6 million at year-end 2023, with total liabilities also increasing to $345.8 million from $329.4 million, primarily due to a rise in long-term debt, resulting in a total stockholders' deficit of $9.2 million | (in thousands) | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Total current assets** | **$173,280** | **$156,264** | | **Total assets** | **$336,616** | **$322,602** | | Total current liabilities | $73,084 | $95,193 | | Long-term debt, net | $229,674 | $190,932 | | **Total liabilities** | **$345,794** | **$329,384** | | **Total stockholders' equity (deficit)** | **($9,178)** | **($6,782)** |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1375 West Fulton Street, Suite 1300 (Address of principal executive offices) (Zip Code) (844) ...